A phase 3 trial evaluating Moderna’s investigational seasonal influenza vaccine, mRNA-1010, found the messenger RNA ...
The hardest problem in any marketplace is not growth — it is knowing what caused it. Nihar V. Patel, a product data scientist ...
Fibrinolysis with anticoagulation may reduce adverse outcomes within 7 days of pulmonary embolism in patients with intermediate-risk PE.
Morning Overview on MSN
A Cadence-Nvidia partnership aims to close the 'sim-to-real' gap — training robots in virtual worlds that actually match reality
A robot arm that can flawlessly sort packages inside a computer simulation will, more often than not, fumble the same task ...
Trial design shift: PDS Biotech added progression-free survival as an interim co-primary endpoint in its Phase III cancer trial to enable a faster FDA review. Cost and size cut: The company reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results